

cancer, infectious diseases, and autoimmune diseases.

FOR FURTHER INFORMATION CONTACT:

Inquiries related to this license opportunity should be directed to: Nikki Guyton, Ph.D., Unit Supervisor, NCI, Technology Transfer Center, Email: darackn@mail.nih.gov or Phone: 240-276-5493.

SUPPLEMENTARY INFORMATION: Cellular immunotherapy holds much promise for the treatment of cancer. However, certain cellular therapies have limited success because of immunosuppression in the tumor microenvironment. Thus, there is an unmet need for improved methods of cellular immunotherapy.

T cells constitutively express inhibitory molecules that limit the activation response to antigens by the T cell antigen receptor (TCR). Among these are the transmembrane adapter proteins SIT1, LAX 1 and TRA T1. These appear to tonically associate with the TCR and inhibit signal transduction. Researchers at the NICHD have identified SIT1, LAX 1 and TRA T1 as potential targets for T-cell immunotherapy. Mouse models have demonstrated that deletion of SIT1, LAX1 and TRA T1—or expression of nonfunctional mutant versions of these proteins in mouse T cells—enhances TCR signaling and significantly increases T cell cytotoxicity against tumor cells. Experiments confirming these results in human T cells are currently underway. This discovery provides a new therapeutic approach to greatly improve clinical outcomes of T-cell immunotherapy in treating cancers. It also holds potential to treat infectious diseases or autoimmune diseases.

This Notice is in accordance with 35 U.S.C. 209 and 37 CFR part 404 and the intellectual property rights have been assigned to the Government of the United States of America.

NIH Reference Number: E-004-2024.

Product Type: Therapeutic.

Therapeutic Area(s): Oncology | Immunology.

Potential Commercial Applications:

- Treatment for cancer.
- Treatment for infectious diseases.
- Treatment for autoimmune diseases.

Competitive Advantages:

- Potentially superior therapeutic benefit in cancer by:
 - Enhancing tumoricidal activity of T-cell immunotherapy.
 - Overcoming immunosuppression in the tumor microenvironment.
- Potentially superior therapeutic benefit in infectious diseases by enhancing immune responses to pathogens.

- Potentially superior therapeutic benefit in autoimmune disease by enhancing the generation or function of antigen-specific regulator T cells (Tregs).

Patent Status: A PCT application was filed on January 24, 2025.

Development Stage: Pre-clinical (*in vivo* validation).

Collaboration Opportunity: Researchers at the NICHD seek licensing for further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases.

Dated: May 6, 2026.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2026-09292 Filed 5-8-26; 8:45 am]

BILLING CODE 4167-05-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Social and Community Influences on Health Integrated Review Group; Health Promotion in Communities Study Section.

Date: June 9–10, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Helena Eryam Dagadu, MPH, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3137 Bethesda, MD 20892, (301) 435-1266 dagadu@csr.nih.gov.

Name of Committee: Population Sciences and Epidemiology Integrated Review Group; Lifestyle and Health Behaviors Study Section.

Date: June 10, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Jewel L. Wright, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive Bethesda, MD 20892, (301) 827-9038 jewel.wright@nih.gov.

Name of Committee: Biological Chemistry and Macromolecular Biophysics Integrated Review Group; Maximizing Investigators' Research Award—E Study Section.

Date: June 11–12, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Vandana Kumari, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496-3290 vandana.kumari@nih.gov.

Name of Committee: Infectious Diseases and Immunology A Integrated Review Group; Molecular and Cellular Biology of Virus Infection Study Section.

Date: June 11, 2026.

Time: 10:00 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Syed Mohammad Moin, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20817, (301) 594-7593 syed.moin@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Infectious Disease Drug Development and Molecular Pharmacology.

Date: June 11, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Ekaterina Mikhailovna Nestorovich, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 827-1367 ekaterina.nestorovich@nih.gov.

Name of Committee: Infectious Diseases and Immunology B Integrated Review Group; Viral Dynamics and Transmission Study Section.

Date: June 11, 2026.

Time: 10:00 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Alfredo J Guerra, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480-2569 alfredo.guerra@nih.gov.

Name of Committee: Bioengineering Sciences & Technologies Integrated Review Group; Biodata Management and Analysis Study Section.

Date: June 12, 2026.

Time: 9:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: E. Bryan Crenshaw, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480-7129 bryan.crenshaw@nih.gov.

Name of Committee: Vascular and Hematology Integrated Review Group; Atherosclerosis and Vascular Inflammation Study Section.

Date: June 12, 2026.

Time: 9:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Courtney Watkins, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496-3093 courtney.watkins2@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Neuropathophysiology of Addictive Substances.

Date: June 12, 2026.

Time: 10:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Eileen Marie Moore, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-8928 eileen.moore@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Institutional Research Training in Comparative Veterinary Medicine (T32).

Date: June 12, 2026.

Time: 11:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Zhuqing Li, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 435-5992 zhuqing.li@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: May 06, 2026.

Bruce A. George,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026-09231 Filed 5-8-26; 8:45 am]

BILLING CODE 4167-05-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Agency Information Collection Activities: Proposed Collection; Comment Request

In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 concerning opportunity for public comment on proposed collections of information, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the information collection plans, call the SAMHSA Reports Clearance Officer on (240) 276-0361.

Comments are invited on: (a) whether the proposed collections of information are necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Proposed Project: Application for the Reviewer Contact Information Form (OMB No. 0930-0255)—Reinstatement

Section 501(h) of the Public Health Service (PHS) Act (42 U.S.C. 290aa), 2 CFR 200.205, and DHHS Grants Policy directs the Assistant Secretary of the Substance Abuse and Mental Health Services Administration (SAMHSA) to

establish a merit review committee to carry out the merit review requirements for applications received for discretionary grant programs. SAMHSA administers large discretionary grant programs under authorization of Title V, and, for many years, SAMHSA has funded discretionary grants to provide substance use and mental health services, research, technical assistance, and training to advance behavioral health and to improve the lives of individuals living with mental and substance use disorders, and their families.

In support of its merit review efforts, SAMHSA desires to continue to expand the quantity and experience of peer reviewers it recruits for their merit reviews of discretionary grant applications. To accomplish that end, SAMHSA has determined that it is important to proactively seek the inclusion of new and qualified individuals. Accordingly, SAMHSA has developed an application form for use by individuals who wish to apply to serve as SAMHSA peer reviewers.

The application form has been developed to capture the essential information about the individual applicants. The most consistent method to accomplish this is through completion of a standard form by all interested people which captures their knowledge, education, and expertise, in a consistent manner. SAMHSA will use the information provided on the form to identify appropriate peer reviewers. Depending on their knowledge, education, and expertise, applicants may be invited to serve on merit review committees.

The following changes are proposed in the form:

1. Changed "Gender" to "Sex".
2. Removed "Transgender" and "Prefer not to Answer" from Sex category.
3. Removed Ethnicity category and combined it with Race/Ethnicity.
4. Added "Middle Eastern or North African" under Race/Ethnicity.
5. Removed "Mixed Race" from Race/Ethnicity category.
6. Removed "LGBTQ" and "Minorities (African American, Hispanic or Latino, etc.)" from Secondary Expertise.
7. Removed the SAMSHA Values That Promote Positive Behavioral Health Statement on page 4.

The following table shows the annual response burden estimate.